Clinical utility of bone marrow flow cytometry in B-cell non-Hodgkin lymphomas (B-NHL).
OBJECTIVE
To determine the efficacy of flow cytometry (FC) in the assessment of bone marrow (BM) in B-cell non-Hodgkin lymphoma (B-NHL). FC is a common practice, but is far from being validated.


RESULTS
Morphological analysis and FC immunophenotyping were performed on 421 samples. T-cell lymphomas, Hodgkin's disease, chronic lymphocytic leukaemia and hairy cell leukaemia were not included in the study. Clonality was assessed by the standard kappa/lambda/CD19 test. Aberrant immunophenotypes present in the B-cell subpopulation were also investigated. A double-step procedure was employed in all cases to increase the sensitivity of the FC procedure. Of 380 evaluable samples, 188 corresponded to follicular lymphoma (FL), 58 to diffuse large B-cell lymphoma (DLBCL), 57 to mantle cell lymphoma (MCL), seven to Burkitt's lymphoma and the remaining 70 samples to other low-grade lymphomas. Morphological marrow infiltration was found in 148 cases, and flow immunophenotyping identified 138 cases with BM involvement. A concordance between the two methods was detected in 298 cases (79%). There was a discordance in 82 cases (21%): morphology positive/FC negative in 46 cases and morphology negative/FC positive in 36 (61% of all cases with discordance were from FL). There was no difference in outcome when patients with discordances were compared with patients without discordances.


CONCLUSIONS
Most samples showed concordance between morphological and FC results. FC identified BM involvement in the absence of morphological infiltration. Morphology/FC discordance seems to have no influence on the outcome of FL patients.
Perea
G
G
Department of Haematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Altés
A
A
Bellido
M
M
Aventín
A
A
Bordes
R
R
Ayats
R
R
Remacha
A F
AF
Espinosa
I
I
Briones
J
J
Sierra
J
J
Nomdedéu
J F
JF
D001853:Bone Marrow / Q000276:immunology / Q000473:pathology*; D018572:Disease-Free Survival; D005434:Flow Cytometry / Q000379:methods*; D006801:Humans; D016130:Immunophenotyping; D016393:Lymphoma, B-Cell / Q000276:immunology / Q000473:pathology*; D008228:Lymphoma, Non-Hodgkin / Q000276:immunology / Q000473:pathology*; D015999:Multivariate Analysis; D011379:Prognosis